Allergan plc

AGN

IE00BY9D5467

Pharmaceuticals

Delayed Nyse Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

27/06	Allergan Aesthetics Debuts Alle Payment Plans	CI
05/03	Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	CI

Zhejiang Chiral Medicine Chemicals Co., Ltd. acquired 90% stake in Actavis Pharmaceutical Co.,Ltd. from Actavis plc.

January 24, 2014 at 09:30 am IST

Zhejiang Chiral Medicine Chemicals Co., Ltd. acquired 90% stake in Actavis (Foshan) Pharmaceutical Co.,Ltd. from Actavis plc (NYSE:ACT) on January 24, 2014.

Zhejiang Chiral Medicine Chemicals Co., Ltd. completed the acquisition of 90% stake in Actavis (Foshan) Pharmaceutical Co.,Ltd. from Actavis plc (NYSE:ACT) on January 24, 2014.

Latest news about Allergan plc

Allergan Aesthetics Debuts Alle Payment Plans	27/06	CI
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	05/03	CI
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	18/23/18	CI
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic)	30/23/30	CI
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM®	15/23/15	CI
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc	18/23/18	CI
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection	17/23/17	CI
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting	07/22/07	CI
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body	31/22/31	CI
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition	03/22/03	CI
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics	13/22/13	CI
PatientFi Expands Partnership with Allergan Aesthetics	06/22/06	CI
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million.	16/21/16	CI
Allergan Aesthetics to Present Data from its Aesthetic Portfolio at the 2021 American Society for Dermatologic Surgery Virtual Meeting	19/21/19	CI
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia	26/21/26	CI
Allergan plc entered into a definitive agreement to acquire Soliton, Inc. for approximately $510 million.	10/21/10	CI
Allergan Aesthetics Launches SkinMedica® Neck Correct Cream	01/21/01	CI
GLOBAL MARKETS LIVE: Alibaba, Nokia, Berkshire Hathaway…	16/21/16
Allergan Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia	25/21/25	CI
PatientFi® Enters into Co-Marketing Agreement with Allergan Aesthetics	08/21/08	CI
Allergan Aesthetics Enters into Option to Acquire Cypris Medical	13/21/13	CI
Street Color: Allergan Reportedly Wins US Import Ban on Jeuveau for 21 Months, Bloomberg Says	17/20/17	MT
Allergan Aesthetics entered into an agreement to acquire Dermal Filler business from Luminera Derm Ltd. for approximately $210 million.	07/20/07	CI
SkinMedica® Launches TNS® Advanced+ Pro-Infusion Serum for DiamondGlow™	30/20/30	CI
Stemson Therapeutics announced that it has received $7.5 million in funding from Allergan plc, Fortunis Capital Limited	16/20/16	CI

Chart Allergan plc

Duration

Period

More charts

Company Profile

Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALLERGAN PLC	+0.97%	6.37TCr
ELI LILLY AND COMPANY	+55.35%	82TCr
NOVO NORDISK A/S	+31.64%	60TCr
JOHNSON & JOHNSON	-0.10%	38TCr
MERCK & CO., INC.	+15.47%	32TCr
ABBVIE INC.	+13.10%	31TCr
ASTRAZENECA PLC	+15.51%	25TCr
NOVARTIS AG	+16.72%	23TCr
AMGEN INC.	+16.54%	18TCr
PFIZER, INC.	+4.31%	17TCr

Other Pharmaceuticals

Allergan plc

Equities

AGN

IE00BY9D5467

Pharmaceuticals

Zhejiang Chiral Medicine Chemicals Co., Ltd. acquired 90% stake in Actavis Pharmaceutical Co.,Ltd. from Actavis plc.

Latest news about Allergan plc

Chart Allergan plc

Company Profile

Sector Other Pharmaceuticals